

# STATE OF NEW YORK

---

4585--A

2021-2022 Regular Sessions

## IN ASSEMBLY

February 4, 2021

---

Introduced by M. of A. RAJKUMAR, LAVINE, GLICK, BICHOTTE HERMELYN, WEPRIN, NOLAN, EICHENSTEIN, HEVESI, SEPTIMO, ANDERSON, BRAUNSTEIN, GALEF, GALLAGHER, COOK, CYMBROWITZ, SEAWRIGHT, FORREST, MAGNARELLI, DILAN -- read once and referred to the Committee on Health -- committee discharged, bill amended, ordered reprinted as amended and recommended to said committee

AN ACT to amend the public health law, in relation to administration of the monoclonal antibody treatment for high risk patients suffering from COVID-19

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. Short title. This act shall be known and may be cited as  
2 the "COVID-19 Early Intervention Act".

3 § 2. Legislative intent. Monoclonal antibody treatment has been shown  
4 to prevent people at high risk of severe COVID-19 disease from hospitalization or death if the treatment is administered within 10 days of  
5 the patient showing symptoms. Even though this FDA-approved treatment  
6 is shown to be life-saving, the treatment is often unused by health care  
7 providers. Drug manufacturer Eli Lilly released a study indicating that  
8 the treatment decreased the rate of hospitalizations and death by 70%.  
9 The intent of this legislation is to require hospitals and other health  
10 providers to inform high risk patients of the availability of the monoclonal antibody treatment and to administer it to consenting patients  
11 where supplies exist. This can include treatment by any drug company  
12 that manufactures the monoclonal antibody treatment, including but not  
13 limited to Eli Lilly or Regeneron.

14 § 3. Section 2182 of the public health law is renumbered section 2183  
15 and a new section 2182 is added to read as follows:

16 § 2182. Monoclonal antibody treatment. 1. Hospitals and health care  
17 providers shall be required to inform patients at high risk of hospital-  
18 ization or severe illness due to COVID-19 of the option of monoclonal  
19  
20

EXPLANATION--Matter in italics (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD09121-05-1

1 antibody treatment where such patient has tested positive for COVID-19  
2 and where such treatment is medically appropriate.

3 2. For the purposes of this section, "high risk" means patients who  
4 have one or more of several qualifying conditions. Qualifying conditions  
5 include either age over sixty-five years, or co-morbidities including  
6 but not limited to advanced chronic kidney disease, heart failure,  
7 pulmonary disease, cystic fibrosis, solid organ or stem cell transplant,  
8 active chemotherapy for acute leukemia, lymphoma, or myeloma,  
9 Parkinson's disease, use of immunosuppressive therapy, diabetes requir-  
10 ing medication, or a body mass index (BMI) greater than thirty-five.

11 3. Hospitals and health care providers shall be required to administer  
12 the monoclonal antibody treatment to high risk patients who consent to  
13 such treatment and where the hospital or provider has access to the  
14 treatment. The treatment must be administered to the patient within six  
15 hours of the patient receiving a positive COVID-19 test result, except  
16 under extenuating circumstances, and within ten days of the patient's  
17 onset of symptoms relating to COVID-19.

18 4. If a hospital or health care provider does not have the treatment  
19 available, they shall assist the patient with the process of obtaining  
20 an appointment or referral to another facility or provider who can  
21 administer the monoclonal antibody treatment within the timeframes set  
22 forth in this section or otherwise specified by the department or the  
23 FDA.

24 5. Each hospital and health care provider shall provide patients with  
25 a form, to be developed by the department, requiring his or her signa-  
26 ture acknowledging that he or she has been informed of the option for  
27 monoclonal antibody treatment and indicating whether or not they elect  
28 to receive such treatment.

29 § 4. This act shall take effect on the thirtieth day after it shall  
30 have become a law.